[{"company":"TenNor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TenNor Therapeutics Received FDA Orphan Drug Designation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"TenNor Therapeutics"},{"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CanSino Biologics"},{"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Receives IND Approval for its HIV Drug ASC09F","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Ascletis Pharma"},{"company":"Sinovac Biotech","sponsor":"Advantech Capital","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinovac Biotech"},{"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Inactivated COVID-19 Vaccine Enters 2nd-Phase Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinopharm"},{"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Dosed First Patient in Phase II Clinical Study of IAP Antagonist APG-1387 in Combination with Entecavir for Chronic Hep B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Ascentage Pharma"},{"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CanSino Vaccine Produces Immune Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CanSino Biologics"},{"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Ascletis Pharma"},{"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Releases Preclinical Results of IAP Antagonist APG-1387 in an Oral Presentation at EASL ILC 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Ascentage Pharma"},{"company":"Shenzhen Kangtai Biological Products","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Kangtai Starts Mid-Stage Trial of its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Shenzhen Kangtai Biological Products"},{"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Proxalutamide's COVID-19 Clinical Trial Shows Significant Reduction in Hospitalization and Ventilation Rates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Kintor Pharmaceutical"},{"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor's Proxalutamide (GT0918) COVID-19 Clinical Trial Shows Positive Preliminary Results in Treatment of Female Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Kintor Pharmaceutical"},{"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor\u2019s Preliminary Result of COVID-19 Trial in Female Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Kintor Pharmaceutical"},{"company":"LianBio","sponsor":"ReViral","pharmaFlowCategory":"D","amount":"$119.0 million","upfrontCash":"$14.0 million","newsHeadline":"ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"LianBio"},{"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces Positive Phase IIa HBV Results on Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Ascletis Pharma"},{"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis 149 Patient Positive Interim Results of Phase IIb Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Ascletis Pharma"},{"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Studies of PD-L1 Antibody ASC22 for HBV Functional Cure Selected for Inclusion in the \"Best of The Liver Meeting's Summary\" by AASLD Review Committee","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Ascletis Pharma"},{"company":"China Resources Pharmaceutical Group","sponsor":"Everest Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Everest Medicines Enters into an MOU for Partnership with China Resources Pharmaceutical Group for its mRNA Vaccine Business","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"China Resources Pharmaceutical Group"},{"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces Oral Presentation on Updates from Phase IIb Clinical Trial of ASC22, a Subcutaneous PD-L1 Antibody for Functional Cure of Chronic Hepatitis B at EASL ILC 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Ascletis Pharma"},{"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announced First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration\/ Functional Cure of HIV-1 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Ascletis Pharma"}]
Details:
ASC22 (Envafolimab) is a subcutaneously administered single domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection.
Lead Product(s):
Envafolimab,Antiretroviral Therapy
Therapeutic Area: Infections and Infectious Diseases
Product Name: ASC22
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 28, 2022
Details:
ASC22 (Envafolimab) is a subcutaneously administered single domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection.
Lead Product(s):
Envafolimab
Therapeutic Area: Infections and Infectious Diseases
Product Name: ASC22
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 15, 2022
Details:
Everest’s licensing partner Providence is currently evaluating PTX-COVID19-B in a head-to-head clinical trial against Pfizer-BioNTech’s Comirnaty COVID-19 vaccine. Everest and Providence also plan to initiate a trial in 2022 to further expand the indication of PTX-COVID19-B.
Lead Product(s):
PTX-COVID19-B
Therapeutic Area: Infections and Infectious Diseases
Product Name: PTX-COVID19-B
Highest Development Status: Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Everest Medicines
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Partnership
April 07, 2022
Details:
The Phase IIa and IIb studies are focused on chronic hepatitis B (CHB) functional cure using a subcutaneously administered PD-L1 antibody ASC22 (Envafolimab).
Lead Product(s):
Envafolimab,Nucleotide Analogs
Therapeutic Area: Infections and Infectious Diseases
Product Name: ASC22
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 16, 2021
Details:
The ASC22 Phase IIb study is a randomized, single-blind, placebo-controlled, multi-center clinical trial in China which evaluates the safety and efficacy of treating patients with CHB for 24-week treatment of 1 mg/kg or 2.5 mg/kg ASC22 or matching placebo.
Lead Product(s):
Envafolimab,Nucleotide Analogs
Therapeutic Area: Infections and Infectious Diseases
Product Name: ASC22
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 27, 2021
Details:
The phase IIa data indicated that there is a trend of dose dependent HBsAg reduction after single dose administration of 0.3, 1.0 or 2.5 mg/kg ASC22. Eight out of nine patients treated with ASC22 exhibited some decline in HBsAg at the end of 12-week follow-up.
Lead Product(s):
Envafolimab
Therapeutic Area: Infections and Infectious Diseases
Product Name: ASC22
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 05, 2021
Details:
Sisunatovir is ReViral’s lead small molecule for the treatment of RSV, currently in Phase 2 clinical studies in pediatric and adult immunocompromised patient populations.
Lead Product(s):
Sisunatovir
Therapeutic Area: Infections and Infectious Diseases
Product Name: RV521
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
ReViral
Deal Size: $119.0 million
Upfront Cash: $14.0 million
Deal Type: Collaboration
March 02, 2021
Details:
The percentage of hospitalization, admission to ICU, mechanical ventilation requirement and death was 1.7% vs. 17.1%, 0% vs. 8.6%, 0% vs. 5.7% and 0%, vs. 2.9% in Proxalutamide and placebo arms respectively.
Lead Product(s):
Proxalutamide
Therapeutic Area: Infections and Infectious Diseases
Product Name: GT0918
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 10, 2021
Details:
According to the latest data from the trial, the percentage of hospitalisation, ICU admission, and the need for mechanical ventilation and death was at 1.7% versus 17.1%, 0% versus 8.6%, 0% versus 5.7% and 0% versus 2.9% in the Proxalutamide and placebo cohorts, respectively.
Lead Product(s):
Proxalutamide
Therapeutic Area: Infections and Infectious Diseases
Product Name: GT0918
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 10, 2021
Details:
Proxalutamide is a new androgen receptor (AR) antagonist developed in by Kintor Pharmaceutical and is currently undergoing phase I-III clinical trials in China and the US for the treatment of prostate cancer and breast cancer.
Lead Product(s):
Proxalutamide
Therapeutic Area: Infections and Infectious Diseases
Product Name: GT0918
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 11, 2020
Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
